Catalog No.
DHE14002
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgM-nd
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Hepatoma-associated antigen, BSG, HAb18G, 5F7, TCSF, OK blood group antigen, Collagenase stimulatory factor, CD147, Leukocyte activation antigen M6, Basigin, Extracellular matrix metalloproteinase inducer, EMMPRIN, Tumor cell-derived collagenase stimulatory factor
Concentration
1.21 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein L purified from cell culture supernatant.
Accession
P35613
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ABX-RB2, CAS: 1427008-29-4,cem2.6
Clone ID
Ziralimumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Impaired health status and the effect of pain and fatigue on functioning in clinical trial patients with systemic lupus erythematosus, PMID: 24085548
S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases, PMID: 33748735
Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature, PMID: 21994039
Systemic Lupus Erythematosus (SLE) Responder Index response is associated with global benefit for patients with SLE, PMID: 29460699
Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials, PMID: 32960720
Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies, PMID: 26270565
Why, why, why de-lupus (does so badly in clinical trials), PMID: 26786849
Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation, PMID: 29869293
Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis, PMID: 28673504
Type I interferon blockade in systemic lupus erythematosus: where do we stand?, PMID: 24344319
Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System, PMID: 26099519
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus, PMID: 34244988
Targeted therapies in systemic lupus erythematosus, PMID: 23963429
Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment, PMID: 24939511
Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis, PMID: 24357810
Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus, PMID: 31565077
From mechanism to therapies in systemic lupus erythematosus, PMID: 28118202
Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?, PMID: 27497254
Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations, PMID: 32237942
Update on clinical trials in systemic lupus erythematosus, PMID: 27314466
Targeting interferons in systemic lupus erythematosus: current and future prospects, PMID: 25940912
Biologic therapy for autoimmune diseases: an update, PMID: 23557513
Interferon targeted therapies in systemic lupus erythematosus, PMID: 32185249
Biologics for idiopathic inflammatory myopathies, PMID: 28817464
Interferon α-targeted therapy, PMID: 23994795
Structural Insights into the Neutralization Properties of the Fully Human, Anti-interferon Monoclonal Antibody Sifalimumab, PMID: 25925951
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study, PMID: 21798883
A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients, PMID: 23434567
Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus, PMID: 23754736
Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients, PMID: 26659791
Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus, PMID: 20392292
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study, PMID: 23400715
Cutaneous lupus erythematosus: updates on pathogenesis and associations with systemic lupus, PMID: 27270345
Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics, PMID: 26767526
Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study, PMID: 30791804
Biologic therapy in the idiopathic inflammatory myopathies, PMID: 31680207
Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus, PMID: 31651869
Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus, PMID: 28000522
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study, PMID: 27009916
For research use only. Not for human or drug use.
